Ocular melanoma

1 trials 1 recruiting MedDRA PT
1 Registered trials
1 Recruiting
1 Unique sponsors
5 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Alkylating agent 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • iOnctura SA Commercial
    DACARBAZINE CITRATE; IPILIMUMAB; NIVOLUMAB; NIVOLUMAB, RELATLIMAB; ROGINOLISIB
    2024-514333-37-00 2 countries 2025 n=43
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
iOnctura SA Commercial 1 Phase II 1
New trials by year
2025
1
← All indication landscapes